Mol Cell Oncol

ISSN	2372-3556
ISSN-L	-
IUID	1f7bcdd18aca4fd086d9243f19dbdb34
Modified	2026-08-20T09:37:42.710Z
Created	2026-08-20T09:37:42.709Z

Year 2022

PubMed DOI Crossref

APOBEC3 as a driver of genetic intratumor heterogeneity.

Venkatesan S, Angelova M, Bartkova J, ..., Kanu N, Swanton C

Mol Cell Oncol 10 (1) 2014734 [2022-01-03; online 2022-01-03]

Year 2020

PubMed DOI Crossref

Targeting tumor vulnerabilities associated with loss of heterozygosity.

Rendo V, Stoimenov I, Sjöblom T

Mol Cell Oncol 7 (4) 1759390 [2020-05-13; online 2020-05-13]

Year 2019

PubMed DOI Crossref

Convergence of EGFR glioblastoma mutations: evolution and allostery rationalizing targeted therapy.

Mol Cell Oncol 6 (5) e1630798 [2019-07-04; online 2019-07-04]

Year 2017

PubMed DOI Crossref

SAMHD1 is a barrier to antimetabolite-based cancer therapies.

Rudd SG, Schaller T, Herold N

Mol Cell Oncol 4 (2) e1287554 [2017-02-03; online 2017-02-03]

Year 2016

PubMed DOI Crossref

Targeting SOX9 for degradation to inhibit chemoresistance, metastatic spread, and recurrence.

Suryo Rahmanto A, Swartling FJ, Sangfelt O

Mol Cell Oncol 4 (1) e1252871 [2016-11-08; online 2016-11-08]

PubMed DOI Crossref

Pleiotrophin is a driver of vascular abnormalization in glioblastoma.

Zhang L, Dimberg A

Mol Cell Oncol 3 (6) e1141087 [2016-02-18; online 2016-02-18]

SciLifeLab Data Centre

Publications 9.5.1